ALT 001
Alternative Names: ALT-001; Alternative RAS pathway modulator - Alterras Therapeutics GmbHLatest Information Update: 18 Dec 2022
At a glance
- Originator Alterras Therapeutics
- Class Anti-inflammatories; Small molecules; Vasodilators
- Mechanism of Action Aminopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pulmonary arterial hypertension
Most Recent Events
- 16 Dec 2022 ALT 001 is available for licensing as of 16 Dec 2022. http://www.alterras-therapeutics.com/
- 01 Dec 2022 Preclinical trials in Pulmonary arterial hypertension in Austria (unspecified route) prior to December 2022 (Alterras Therapeutics GmbH pipeline, December 2022)
- 01 Apr 2021 Pharmacodynamics data from preclinical studies in Pulmonary arterial hypertension released by Alterras Therapeutics GmbH